Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimerâs disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimerâs disease from a small sample of blood.
The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026.
The company was incorporated in 1998 and is based in Austin, Texas.
